You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In a genetic population health study, the test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes, Renown Institute said.
The consortium, recently funded with €750,000, is developing a computational tool for identifying NAFLD patients at high risk of progressing to NASH.
The firm intends to commercialize a probe that includes exhaled limonene and other biomarkers to enable clinicians to better identify disease stages.
The blood test will be available to specialty and primary care physicians across the US and Canada from LabCorp by early 2021.
The financing round was led by Asian private investment firm AT Capital and early-stage deep-tech venture capital fund Elev8.vc.
The company is initiating studies to detect responses to treatments for NASH, which may lead to an application for an FDA premarket approval.
Luminist Labs is developing diagnostic technology for liver disease, which DiscernDx will integrate into its precision medicine platform.
The companies will use ProSciento's Nash Pass patient registry and Nordic Bioscience's biomarker technology to validate the translational biomarkers.
The partners said that the first project will focus on the discovery of breath biomarkers for chronic liver diseases and liver-related cancers.
The partners plan to validate the accuracy, effectiveness, and clinical implications of Group K's MultiNostic liver function test, which is pending FDA clearance.